| |
| | MedWatch - Zyprexa (olanzapine) Dear Doctor Letter |
 | | The Food and Drug Administration (FDA) has asked all manufacturers of atypical antipsychotic medications, including Lilly, to add a Warning statement describing the increased risk of hyperglycemia and diabetes in patients taking these medications, including Zyprexa. |
 | | In addition to Zyprexa, the atypical antipsychotic class includes Clozaril ® (clozapine, Novartis), Risperdal ® (risperidone, Janssen), Seroquel ® (quetiapine, AstraZeneca), Geodon ® (ziprasidone, Pfizer), and Abilify ® (aripiprazole, Bristol Myers Squibb and Otsuka American Pharmaceutical). |
 | | Accordingly, the Zyprexa prescribing information has been updated with the following information: |
| www.fda.gov /medwatch/SAFETY/2004/zyprexa.htm (448 words) |
|